The global nutrigenomics market size was valued at USD 1,241.61 million in 2022. It is estimated to reach USD 5,205.59 million by 2031, growing at a CAGR of 17.26% during the forecast period (2023–2031).
According to the National Cancer Society, Nutrigenomics is the study of a person's gene and its interaction with the food consumed by the person. Nutrigenomics is also referred to as "nutritional genomics." The study lays the foundation for the concept of "personalized nutrition." The research field is highly dependent on the recent developments and advancements of the technologies that allow processing of large amounts of data relating to gene variants. Nutrigenomics aids in examining a person's risk of contracting a disease and the impact of bioactive food components and nutrients on gene expression. Several samples, including blood, buccal swabs, saliva, and others, are used in nutrigenomics testing.
Nutrigenomics, which involves the genetic manipulation of crops and animal feed, may also impact the various food chain links. Nutritional genomics investigates the effects of metabolites and dietary components using different omic techniques. Genomic, proteomic, transcriptomic, metabolomic, epigenomic, and metagenomic technologies are examples of omic technologies. The concept of nutrigenomics was explored to build future tools for personalized nutrition, health maintenance, and disease prevention.
The value of food as medicine was acknowledged several years ago by Hippocrates. An optimal diet can majorly prevent coronary heart disease, diabetes, cancer, obesity, etc. Personalized nutrition harnesses personalized nutrition, allowing the analysis of a person's genetic makeup. The ability of preventive healthcare or medicine to stop the disease before its occurrence has led to an increased focus on exploring personalized nutrition for the early management of various diseases. The rapid progress of genomic sequencing, omics technology, and the ability to manage the disease early has imposed strong attention on preventive healthcare.
Additionally, preventive medical nutrition focuses on erasing the probability of the origin of the disease. Moreover, the specific field of Metabonomics has emerged to deal with the study of the estimation of metabolic responses based on nutrient deficiency or sufficiency, which is a way to characterize the metabolic phenotype of individuals and predict their respective interactions with the environment, gut microbiota, and behavior. It also has a significant role in personalized nutrition management and disease prevention. Thus, the increasing demand for preventive medicine through personalized nutrition drives the nutrigenomics market growth.
Non-communicable diseases, often known as lifestyle diseases or diseases not caused by infectious agents, have become more commonplace worldwide. According to the World Health Organization (WHO), in 2021, non-communicable diseases killed 41 million people globally. The major NCD risk factors include physical inactivity, smoking, excessive salt/sodium intake, high alcohol consumption, and obesity. These factors constitute what is known as a sedentary lifestyle, which is the biggest reason for NCD-related deaths.
The global market is anticipated to grow dramatically due to increased nutrigenomic research focusing primarily on chronic disorders. Rising awareness and precautionary regulations such as taxes being implemented upon these high-calorie and high-carbohydrate foods are conjunctively impacting the rising awareness among the global population to switch to healthier diets and take preventive measures to avoid manifestations of NCDs. Such factors drive the market's growth.
The supporting data regarding the appropriate usage and implementation of nutrigenomics still needs to be increased. Probiotics are popular due to preexisting assumptions about their advantages; nevertheless, further research is required to support the therapeutic potential of the other items in development. These factors lead to inadequate measures to aid the market pull. Advertisements regarding these products require the proper establishment of accurate scientific data that quantifies the benefits of using these therapeutics. The lack of scientific data and insufficient research prevents market-pulling operations from taking place, restraining the expansion of the global market.
Due to rapidly advancing research in the field and the successful publication of findings from significant initiatives conducted worldwide, interest in nutrigenomics has increased. Projects undertaken globally, including the HMP and iHMP, have revolutionized chronic disease treatments as many companies focus on designing and developing new therapeutics. Additionally, these research programs have been heavily funded, showcasing this field's high potential.
Since HMP received USD 215 million (for phase 1 and phase 2) in funding from organizations led by the NIH, funding opportunities have only increased for companies trying to harness the microbiome. More than 35 funding opportunities for some of the leading players in the market that target microbiome modification were given between January 2014 and August 2018. In addition, prominent venture capitalists such as Seventure Partners and Flagship Ventures have led these funding opportunities by pumping large amounts into companies of all valuations, including start-ups. These figures signify the money going into microbiome research and exhibit the lucrative opportunities for nutrigenomics when commercialized.
The global nutrigenomics market is segmented by application, service, and products.
Based on application, the global market is bifurcated into women's health, digestive health, immune health, and others.
The digestive health segment dominates the global market and is anticipated to grow at a CAGR of 15.44% over the forecast period. The human gastrointestinal tract is home to a highly complex and diverse microbial community, with microbial cells outnumbering human cells with a ratio of 10:1. Disruption of the gut microbiota is increasingly being realized to be highly significant for metabolic diseases such as malnutrition, diabetes, chronic inflammatory bowel diseases (both ulcerative colitis and Crohn's Disease), and pathological diseases such as C. difficile infections and Enterotoxic E. coli infections. The connection between disruptions in the gut microbiome and metabolic diseases has been well-documented through tools like high-throughput sequencing, 16s rRNA sequencing, and non-genomic techniques, leading to a very high number of therapeutic interventions for gut-related illnesses.
The immune system within the human body is composed of a highly complex network of innate and adaptive components endowed with an extraordinary ability to adapt and respond to diversified challenges. Collectively acting as a formidable regulator of cellular homeostasis within the host, this intricate system allows the sustenance and restoration of tissue function for encounters of environmental and microbial natures. The coincidence of the defined arms of the immune system with the acquired microbiota has been well-documented to exert a symbiotic relationship for the optimal functioning of human machinery.
Based on service, the global market is divided into nutrigenomics testing market for clinical purposes and for research purposes.
The nutrigenomics testing market for clinical purpose segment is responsible for the highest market share and is anticipated to exhibit a CAGR of 14.09% over the forecast period. Genes code every aspect of our health and are the building blocks of our life. Hence, gaining optimum health and well-being requires an efficient knowledge of our genes. Various aspects of health are directly or indirectly governed by the nutrition we take and impact our genes. The predictive testing of such genes with the help of technology can assist in analyzing our health and can reduce the risk of disease conditions through lifestyle management. Further, the predictive testing of the genes also eliminates the idea of a "one size fits all" approach to the healthcare system. It would offer a personalized solution as per the individual's genetic composition.
Based on products, the global market is segmented into prebiotics and probiotics.
The probiotics segment owns the highest market share and is expected to grow at a CAGR of 16.43% during the forecast period. Probiotics are live microbes that are consumed for health benefits. Probiotics have well-documented effects on the gut microbiome, led by the effects conferred by the first-ever commercialized probiotic, Yakult. A dairy-based probiotic drink, Yakult was launched in 1935 and has been extensively used worldwide, turning over monumental amounts of sales.
Prebiotics are generally described as substrates that aid in the growth of beneficial microbes inside the human body, primarily the gut, which helps maintain the microbial equilibrium in the body. The improved knowledge regarding the composition of the human microbiota and advancing studies into designing the optimal nutritional supplement for the beneficial microbes within the human body have provided a broader scope for categorizing prebiotics. With the increasing number of microbes having modulatory capabilities within the human microbiota and the expanding knowledge regarding the different effects conferred by the interaction of different compounds with the human microbiota, prebiotics has become more inclusive concerning nutritional supplements.
Based on region, the global nutrigenomics market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.
North America is the most significant global nutrigenomics market shareholder and is anticipated to exhibit a CAGR of 20.10% during the forecast period. The North American nutrigenomics market is expected to be driven by the growing prominence of health-conscious dietary habits and technological advancements. A high prevalence of different medical conditions, such as obesity, lactose intolerance, and inflammatory bowel disease in the region, fuels the market growth. Additionally, substantial investments in nutrigenomic testing and diet due to increasing health awareness further drive regional market growth. Similarly, establishing reimbursement scenarios by developing evidence-based authorized data proving several benefits of nutrigenomic supplements provides tremendous opportunities for market growth in the region. Moreover, the collaboration of key market players with physicians to promote the adoption of a nutrigenomic diet and testing will enhance the future market growth. The U.S. was the leading contributor to the North American market owing to the launch of genetic testing and food items focusing on nutrigenetics.
Europe is estimated to exhibit a CAGR of 16.98% over the forecast period. The Europe nutrigenomics market is a lucrative market with immense growth potential. Growing consciousness of the health disorders resulting from a change in lifestyles, increasing prominence of preventive medicine and health-conscious dietary habits, raising awareness about the diet-disease relationship, and growing geriatric population are the significant factors driving the regional market growth. The nutrigenetics-based diet and genetic tests are most widely used in the developing nations of Central and Eastern Europe. In addition, several European countries, including France, Germany, the U.K., France, Spain, and Italy, are working persistently to enhance the adoption of nutrigenomics genetic testing for children across Europe. In contrast to the leading countries contributing significantly to the Europe market, the market for nutrigenomics in Germany is anticipated to see the highest growth in the forecast period. Furthermore, investments in genetic testing by the leading firms to promote the adoption of genetic testing and usage of probiotic-based supplements are fuelling the development of the nutrigenomics market in Germany.
The expanding economies in the Asia-Pacific region are witnessing an improving awareness of the nutrigenetics-based diet and genetic tests. The expanding population of the region and increasing genetic association of several diseases impacted by dietary patterns has fueled the expansion of the market. In addition, the rising prevalence of different types of digestive illnesses, such as inflammatory bowel disease (IBD), lactose intolerance, and gastrointestinal disorders, is stimulating the market growth in the region. The growing awareness about the diet-disease relationship is increasing the demand for genetic tests in the region. Also, increasing demand for health-conscious dietary products is boosting the market growth in the region.
The Latin America nutrigenomics market is anticipated to grow considerably in the forecast period. The region holds a significant opportunity for expansion by the key players of the global market. The growing geriatric population of the region and the high prevalence of several digestive diseases are the pivotal factors propelling the growth of the Latin American market. Moreover, the emergence of nutrigenomic testing has also paved a mode of market expansion in the region. However, ambiguous food supplement regulations hamper nutrigenomics growth in Latin America.
The Rest-of-the-World region constitutes the Middle East, Africa, the Caribbean, and Oceania regions. The predicted growth is attributed to the rise in the prevalence of different digestive disorders and the growing prominence of preventive medicine. Further, the increasing awareness of the benefits associated with probiotics propels the growth of the Rest-of-the-World nutrigenomics market.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
"Find new revenue generation opportunities"